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SUMMARY
One-carbon (1C) units for purine and thymidine syn-
thesis can be generated from serine by cytosolic or
mitochondrial folate metabolism. The mitochondrial
1C pathway is consistently overexpressed in cancer.
Here, we show that most but not all proliferating
mammalian cell lines use the mitochondrial pathway
as the default formaking 1C units. Clustered regularly
interspaced short palindromic repeats (CRISPR)-
mediated mitochondrial pathway knockout activates
cytosolic 1C-unit production. This reversal in cyto-
solic flux is triggered by depletion of a single
metabolite, 10-formyl-tetrahydrofolate (10-formyl-
THF), andenables rapid cell growth innutrient-replete
conditions. Loss of the mitochondrial pathway, how-
ever, renders cells dependent on extracellular serine
to make 1C units and on extracellular glycine to
make glutathione. HCT-116 colon cancer xenografts
lacking mitochondrial 1C pathway activity generate
the 1C units required for growth by cytosolic serine
catabolism. Loss of both pathways precludes xeno-
graft formation. Thus, either mitochondrial or cyto-
solic 1C metabolism can support tumorigenesis,
with the mitochondrial pathway required in nutrient-
poor conditions.
INTRODUCTION
Tetrahydrofolate (THF) is the cofactor required for the activation
and transfer of one-carbon (1C) units for nucleotide biosynthesis
and methionine regeneration. Dietary folate is essential, and
folate deficiency is a leading cause of birth defects (World
Health Organization, 2008). Pharmacological inhibition of 1C
metabolism with folate analogs (antifolates) was one of the first
chemotherapies, and antifolates remain mainstays of cancer
treatment. Unfortunately, existing agents, which broadly inhibit
folate-mediated reactions, result in substantial side effects,
including impaired hematopoiesis and damage to the gastroin-
testinal epithelium. Despite extensive research into antifolates,
the biological function of specific folate enzymes in different
physiological and pathological contexts is only now being
elucidated.
In cancer, certain 1C genes are consistently overexpressed.
These include DHFR (dihydrofolate reductase), an enzyme
strongly inhibited by current antifolates, and TYMS (thymidylate
synthase), the target of the important chemotherapeutic 5-fluo-
rouracil (Huennekens, 1994; Longley et al., 2003). Equally upre-
gulated are two genes of mitochondrial 1C transformations:
SHMT2 (mitochondrial serine hydroxymethyl transferase) and
MTHFD2 (mitochondrial methylenetetrahydrofolate dehydroge-
nase) (Jain et al., 2012; Lee et al., 2014; Nilsson et al., 2014).
Together, these enzymes, both of which lie in a pathway essen-
tial for embryonic development (Di Pietro et al., 2002; Momb
et al., 2013), transform serine into glycine and a formyl
unit attached to THF (Figure 1A). Interestingly, production of
serine itself is frequently upregulated in cancer, with the first
enzyme of serine synthesis, 3-phosphoglycerate dehydroge-
nase (PHGDH), often genomically amplified in breast cancer
and melanoma (Locasale et al., 2011; Possemato et al., 2011).
Expression of both serine biosynthesis and the mitochondrial
1C pathway can be driven by the transcription factor ATF4,
which can be activated by mTORC1 and NRF2-KEAP1 signaling
(Ben-Sahra et al., 2016; DeNicola et al., 2015). Thus, cancers
commonly overexpress the enzymes to make serine and con-
vert it into glycine and mitochondrial 10-formyl-tetrahydrofolate
(10-formyl-THF).
Mitochondrial 10-formyl-THF is needed to make formyl-
methionine for mitochondrial protein synthesis (Tucker et al.,
2011). The required amount is small, however, and methio-
ninyl-tRNA formyl-transferase is not upregulated in cancer
(Nilsson et al., 2014). Mitochondrial 10-formyl-THF may also
be used to generate cytosolic 1C units; while carbon bearing
THF species do not cross the mitochondrial membrane, mito-
chondrial 10-formyl-THF can be cleaved by methylenetetrahy-
drofolate dehydrogenase 1-like (MTHFD1L) into free formate,
which can cross the mitochondrial membrane and be assimi-
lated in the cytosol by methylenetetrahydrofolate dehydroge-
nase (MTHFD1) (Figure 1A). Embryonic defects induced by
deletion of MTHFD1L are partially rescued by formate (Momb
et al., 2013).
A puzzling aspect of the essentiality of mitochondrial folate
metabolism in development and its upregulation in cancer is
the existence of a parallel cytosolic pathway that is sufficient to
support cell growth in culture (Patel et al., 2003; Tibbetts and
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Appling, 2010). Cytosolic serine hydroxymethyl transferase
(SHMT1) can use serine tomake cytosolic 5,10-methylene-tetra-
hydrofolate (methylene-THF), which is poised to carry out all of
the major physiological functions of 1C units: direct use for
thymidine synthesis, reduction to 5-methyl-THF to serve as a
1C donor for methionine synthase, or oxidation to 10-formyl-
THF for purine biosynthesis. While other substrates, including
glycine and choline, can donate 1C units exclusively to the mito-
chondrial 1C pool, these substrates have not been shown to
contribute significantly to the activated cytosolic 1C pool (Fan
et al., 2014; Jain et al., 2012; Labuschagne et al., 2014).
One possible advantage of compartmentalization of 1C meta-
bolism involves redox homeostasis. Folate metabolism can pro-
duce mitochondrial NADPH via the enzyme ALDH1L2 and
potentially also MTHFD2 (Fan et al., 2014; Lewis et al., 2014)
and knockdown of SHMT2 in certain cancer cell lines increases
their vulnerability to oxidative stressors (Kim et al., 2015; Ye
et al., 2014). The NADPH/NADP+ ratio in turn may play an impor-
tant role in regulating the cytosolic flux of 1C units through the
MTHFD1 dehydrogenase reaction. The relatively high NADPH/
NADP+ ratio in the cytosol may favor reduction of 1C units
from 10-formyl-THF into methylene-THF, whereas low NADH
levels in the mitochondria favor the opposite (Pelletier and
MacKenzie, 1995).
To explore the function of compartmentalized 1C metabolism,
we created using clustered regularly interspaced short palin-
dromic repeats (CRISPR) a panel of isogenic clonal folate
enzyme deletion cell lines. We find that the mitochondrial
pathway is the default in most but not all cancer cells. Intrigu-
ingly, folate metabolism is both plastic and self-regulating; loss
of the mitochondrial pathway triggers, through depletion of cyto-
solic 10-formyl-THF, de novo generation of 1C units in the
cytosol. While well tolerated in nutrient-replete conditions, this
switch renders cells dependent upon extracellular serine and
glycine to support biosynthesis and antioxidant defense. Despite
these liabilities, HCT-116 colon cancer cells with engineered
mitochondrial 1C enzyme deletions can form xenograft tumors,
by generating cytosolic 1C units from serine via the enzyme
SHMT1. However, loss of both the mitochondrial folate pathway
and SHMT1 inhibits tumorigenesis.
RESULTS
An Isogenic Library of Folate Metabolic Enzyme
CRISPR-Deletion Mutants
HEK293T cells were transiently transfected with Cas9 together
with guide RNA pairs targeting folate genes (Ran et al., 2013a,
2013b). Single colonies were picked from the transfected cells,
and deletions confirmed by Sanger sequencing and western
blotting (Figures 1B and S1A–S1E). We isolated multiple viable
clones deleted for each core enzyme of the mitochondrial
folate pathway (SHMT2/MTHFD2/MTHFD1L/ALDH1L2) and for
the corresponding cytosolic enzymes SHMT1 and ALDH1L1
(Figures S1F–S1K). We did not detect expression of the adult-
specific MTHFD2L isozyme in HEK293T cells (Bolusani et al.,
2011). In the cytosol, the MTHFD1 protein contains separate
domains that correspond to the catalytic activities of both
MTHFD2 and MTHFD1L. Loss of these activities blocks both
known routes of cytosolic 10-formyl-THF synthesis (from either
methylene-THF or free formate). Because cytosolic 10-formyl-
THF is required for purine synthesis, MTHFD1 deletion is ex-
pected to be intolerable. Consistent with this, no MTHFD1
knockout clone was ever isolated, although we did isolate hypo-
morphic MTHFD1 cell lines with reduced enzyme expression
(Figure S1G).
Compensatory changes in the expression of folate pathway
enzymes in deletion clones were limited. Cytosolic pathway
protein levels and MTHFD2 levels were largely unaffected.
Across multiple clones, however, deletion of SHMT1 decreased
SHMT2, whereas deletion of SHMT2 increased SHMT1 (Figures
S1H and S1I). In addition, deletion of MTHFD1L decreased the
abundance of ALDH1L2 (Figure S1K). Overall, each of the single
gene deletions grew well, without a significant decrease in
growth rate for SHMT1, MTHFD2, or MTHFD1L mutant cells
and a modest reduction in growth rate for SHMT2 and ALDH1L2
mutant cells (Figure 1C).
Mitochondrial Folate Pathway Knockout Depletes
10-Formyl-THF and Elevates AICAR
To investigate how cellular metabolism responds to targeted
deletion of folate enzymes, we analyzed the water soluble me-
tabolome of the deletion mutants using liquid chromatography
mass spectrometry (LC-MS) (Figure 1D). A variety of changes
occurred that were not connected to 1C metabolism by known
mechanisms, including increased UDP-sugars upon deletion of
the cytosolic enzymes SHMT1 and ALDH1L1, decreased sugar
bisphosphates upon deletion of the mitochondrial enzymes
MTHFD2 and MTHFD1L, and decreased tricarboxylic acid
(TCA) cycle intermediates upon depletion of SHMT2. However,
the strongest metabolic change by far occurred in 5-aminoimi-
dazole carboxamide ribonucleotide (AICAR; also known as
ZMP).
AICAR is the final intermediate in the de novo purine biosyn-
thesis pathway, and its conversion to inosine monophosphate
(IMP) requires 10-formyl-THF (Figure 1F). While loss of the cyto-
solic enzyme SHMT1 resulted in 5-fold decreased AICAR,
Figure 1. Mitochondrial Folate Metabolism Mutants Are Deficient in 10-Formyl-THF
(A) Folate-mediated 1C metabolism occurs in linked cytosolic and mitochondrial pathways.
(B) Western blot of 1C metabolic enzymes in HEK293T cells in which specific genes were deleted using CRISPR/Cas9.
(C) Doubling times of deletion cell lines cultured in DMEM ± 1 mM sodium formate. Error bars are ± 95% confidence interval of the doubling time fit.
(D) Normalized intracellular levels of water-soluble metabolites in folate pathway deletion cell lines. For each cell line, three individual biological replicates are
shown, normalized to WT cells analyzed in parallel by LC-MS.
(E) LC-MS trace of AICAR (m/z 337.055 ± 2 ppm) in folate-gene-deletion cells.
(F) Metabolite levels of purine biosynthetic intermediates normalized to WT cells as in (D).
(G) 1 mM formate reverses AICAR accumulation in mutant cell lines.
(H) Relative levels of folate species in mutant cell lines. THF and methylene-THF interconvert in cell extracts and accordingly are reported together. All results
(unless stated) are mean ± SD (nR 3 biologic replicates) and were confirmed in independent experiments.
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deletion mutants for the core mitochondrial folate metabolism
enzymes SHMT2, MTHFD2, and MTHFD1L manifested between
50- and 500-fold increases (Figure 1E). The other purine bio-
synthetic intermediate immediately upstream of a step requiring
10-formyl-THF, glycineamide ribonucleotide (GAR), was also
elevated in these cell lines (Figure 1F). Moreover, AICAR was
strongly elevated in the MTHFD1 hypomorphic cells, which are
defective in both routes of making cytosolic 10-formyl-THF (Fig-
ure 1D). Collectively, these observations suggest that wild-type
(WT) HEK293T cells make most cytosolic 10-formyl-THF from
mitochondrial 1C units, which are excreted as formate and re-
assimilated by MTHFD1.
To prove the link between AICAR and formyl unit availability,
we fed cells 1 mM formate, which is present in human serum
at 20–30 mM (Hanzlik et al., 2005; Lamarre et al., 2014). Although
addition did not rescue themodest growth defects of the SHMT2
and ALDH1L2 knockout cells (Figure 1C), it fully reversed the
AICAR elevation in each of the mitochondrial folate pathway
deletion lines (Figure 1G), but not in the MTHFD1 hypomorphic
line (Figure S1L). To prove that loss of themitochondrial pathway
depletes 10-formyl-THF, we directly measured cellular folate
species using LC-MS. These measurements, which cannot
distinguish between THF and methylene-THF due to abiotic
exchange (Ja¨gerstad and Jastrebova, 2014), revealed selective
10-formyl-THF depletion in the mitochondrial folate pathway
enzyme knockouts (Figure 1H). Thus, AICAR reports on cytosolic
formyl units, with the mitochondrial folate pathway required to
maintain normal levels of cytosolic 10-formyl-THF.
1C Units Are Generated Exclusively in the Mitochondria
in Most, but Not All, Cultured Cells
To directly track mitochondrial versus cytosolic 1C unit produc-
tion, we employed an isotopic tracer assay. Cells were fed
[2,3,3-2H]serine and monitored for subsequent labeling of thymi-
dine triphosphate (dTTP) (Herbig et al., 2002). Serine has been
reported to be the predominant 1C donor in cultured cells (Fu
et al., 2001; Labuschagne et al., 2014), and we confirmed that
in HEK293T cells it accounted for essentially all (>98%) of 1C
units incorporated into biomass building blocks (thymidine and
purines; there was no detectable synthesis of methionine; Fig-
ures S2A and S2B). Thymidine is made from cytosolic methy-
lene-THF. Direct production of methylene-THF by SHMT1 will
generate M+2 deoxythymidine trisphosphate (dTTP), whereas
either cytosolic exchange flux between methylene-THF and
10-formyl-THF or transfer of 1C units from the mitochondrion
to cytosol will result in M+1 dTTP (Figure 2A). In WT or SHMT1
deletion HEK293T cells, after correction for natural isotope
abundances (see Experimental Procedures), no M+2 dTTP was
detected. In contrast, knockout of any of the mitochondrial
pathway enzymes resulted in majority M+2 dTTP (Figure 2B).
Consistent with a prior report using this tracer in engineered
mouse embryonic fibroblasts (Pike et al., 2010), this result
validates the tracing strategy and confirms that the M+1 form
arises primarily from mitochondrial 1C production rather than
MTHFD1 reversibility. Furthermore, it definitively demonstrates
that HEK293T cells normally process 1C units oxidatively in the
mitochondria followed by reductive reincorporation of formate
in the cytosol. When mitochondrial folate metabolism is in-
hibited, cells can adapt by reversing cytosolic flux.
We next investigated mitochondrial versus cytosolic 1C unit
production across a spectrum of proliferating cultured cell lines
(quiescent cells do not synthesize dTTP and thus cannot be
probed by this assay). These cell lines included a diversity of
cancers, as well as primary human foreskin fibroblasts (HFFs)
and proliferating 3T3-L1 pre-adipocytes. In the majority of cells
only M+1 dTTP was observed, demonstrating that most cyto-
solic 1C units come from mitochondrial folate metabolism (Fig-
ure 2C). In some cell lines, however, including the transformed
renal epithelial line iBMK, the prostate cancer line LNCaP, and
pancreatic cancer line 8988T, we observed a strong M+2 peak
in dTTP. In the iBMK cells and LNCaP cells, we observed a
labeling pattern intermediate between WT and mitochondrial
pathway knockout HEK 239T cells, suggesting 1C unit genera-
tion in both the cytosol and mitochondria. In 8988T cells, the
pattern matched the engineered mitochondrial knockout cells,
suggesting a sole reliance on cytosolic 1C generation. Thus,
while most cultured cells produce 1C units exclusively in the
mitochondria, some cells show mixed usage or a sole reliance
on the cytosolic pathway.
Formyl-THF Depletion Enables Cytosolic 1C Unit
Production
To explore the mechanism underlying reversal of cytosolic 1C
unit flux in the mitochondrial folate enzyme knockout cells, we
introduced [13C]formate and monitored its incorporation via
formyl-THF into ATP. WT or SHMT1 knockout cells incorpo-
rated a mixture of the exogenously provided [13C]formate
and endogenously generated 1C units exported from the mito-
chondria as unlabeled formate (Figure 2D), with the extent of
ATP and dTTP labeling dependent on the added formate con-
centration (Figures S2C and S2D). Added formate further
labeled serine in an SHMT-dependent manner (Figure S2E).
In contrast, cells with the mitochondrial pathway deleted
assimilated almost solely the exogenously provided formate
(Figure 2D), which alleviated their chronic cytosolic 10-
formyl-THF deficiency as indicated by normalization of AICAR
(Figure 1G).
We then evaluated the exogenous formate concentration
required to outcompete endogenous mitochondrial formate
production (inWT cells) or to drive reductive 1C flux in the cytosol
(in MTHFD2 mutant cells). To this end, cells were cultured in a
fixed concentration of [2,3,3-2H]serine and dTTP labeling was
monitored upon formate titration (Figure 2E). In WT cells, the
half maximal inhibitory concentration (IC50) for inhibition of serine
dTTP labeling by formate was 800 mM, suggesting that endoge-
nous mitochondrial production yields cytosolic formate concen-
trations in this range. In the MTHFD2-deletion cells, the IC50 for
inhibiting cytosolic derived serine dTTP labeling was 140 mM.
Thus, mitochondrial folate metabolism produces cytosolic
formate concentrations 40-fold higher than circulating formate
and 6-fold higher than required to drive cytosolic flux in the di-
rection of formyl-THF reduction.
Building from the observation that mitochondrial-deletion cells
readily used formate, we examined the effects of sudden formate
removal on 1C metabolism (Figure 2F). Within 5 min, AICAR rose
50-fold and 10-formyl-THF fell by roughly 10-fold (Figures 2G
and 2H). Using the [2,3,3-2H]serine tracer, we simultaneously
monitored the appearance of M+2 labeling in 5-methyl-THF
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and dTTP (Figure 2I). Such M+2 labeling was absent in the
presence of formate and rose rapidly over the first 30 min
after formate removal, indicating immediate cytosolic pathway
activation.
Reversal of the cytosolic pathway from 10-formyl-THF reduc-
tion to methylene-THF oxidation requires switching the thermo-
dynamically favored direction of the MTHFD1 methylene-THF
dehydrogenase-cyclohydrolase reaction sequence:
DG=DG
0 +RTln
½NADP+ ½methylene­THF½H2O
½NADPH½10­formyl­THF

:
(Equation 1)
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Figure 2. Cytosolic 1C Flux Is Reversed in Mitochondrial Mutants Due to 10-Formyl-THF Depletion
(A) Schematic of [2,3,3-2H]serine labeling into thymidine (dTMP). Cytosolic production of methylene-THF directly from serine (red circles) results in doubly 2H-
labeled dTMP, whereas its production from 1C units initially generated in mitochondria (blue circles) produces singly 2H-labeled dTMP. Reversibility of MTHFD1
could potentially produce singly labeled dTMP from cytosol-derived 1C units.
(B) Thymidine (dTTP) labeling in WT and mutant HEK293T cells reveals cytosolic 1C-unit generation (dTTP M+2) solely in the mitochondrial pathway mutants.
Labeling fractions are corrected for natural isotope abundances.
(C) [2,3,3-2H]serine labeling into dTTP in different proliferating cell lines. Cytosolic 1C metabolism (dTTP M+2) is evident only in a minority of cell lines.
(D) Exogenous formate (1 mM) is incorporated into ATP via 10-formyl-THF, whose labeling fraction was calculated from the ATP mass isomer distribution.
(E) Formate competes with [2,3,3-2H]serine for labeling of dTTP.
(F) Design of experiment probing cytosolic pathway reversal mechanism. Cells lacking the mitochondrial pathway are initially fed formate, resulting in flux from
10-formyl-THF toward methylene-THF, i.e., upward in (A). Formate is then suddenly removed and metabolic changes monitored. Cytosolic flux directly from
[2,3,3-2H]-serine to methylene-THF was tracked as dTTP M+2 and 5-methyl-THF M+2.
(G) AICAR increases immediately upon formate withdrawal. Signal normalized to time 0.
(H) 10-formyl-THF, but not THF, levels drop upon formate withdrawal.
(I) M+2 dTTP and 5-methyl-THF appear immediately upon formate withdrawal, indicating a switch to cytosolic production of methylene-THF directly from serine
(mean ± SD, nR 3).
(J) NADPH/NADP+ ratio after formate withdrawal from mthfd2D cells.
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In the default reductive direction, the major substrates are
10-formyl-THF and NADPH, which make methylene-THF
and NADP+. Upon formate removal, the NADPH/NADP+ ratio
increased slightly (Figure 2J), consistent with this reaction
now making rather than consuming NADPH; this change,
however, works against the necessary change in reaction
free energy. Thus, the large decrease in 10-formyl-THF upon
formate removal is sufficient to switch the thermodynamically
favored direction of these reactions from consuming to making
10-formyl-THF. This mechanism, mediated by the concentra-
tion of a single metabolite, renders folate metabolism, at least
under favorable nutrient conditions, robust to loss of the mito-
chondrial pathway.
Folate Metabolism Can Produce Either Mitochondrial or
Cytosolic NADPH
Oxidation of methylene-THF to 10-formyl-THF is coupled to
reduction of NAD(P)+ to NAD(P)H depending upon the compart-
ment in which it occurs. The associated redox-active hydrogen
can be labeled by feeding with [2,3,3-2H]serine. Compartmen-
talization and cofactor usage can then be explored based on
passage of the 2H-label into downstream NAD(P)H products.
Fatty acid synthesis specifically uses cytosolic NADPH, with
14 NADPH consumed per palmitate (Figure 3A). Consistent
with 1C unit oxidation occurring in mitochondria, no labeling
of palmitate was observed in WT HEK293T cells (Figure 3B).
Labeling was, however, observed in HEK293T mutants defec-
tive in mitochondrial 1C metabolism and in the 8988T pancre-
atic cancer cell line with an apparent intrinsic defect in mito-
chondrial 1C metabolism (Figures 3B and 3C). This change in
labeling was not due to changes in cellular NADPH levels (Fig-
ure S3A). The quantitative contribution of folate metabolism to
cytosolic NADPH, after correcting for the 2H-kinetic isotope
effect (KIE) (see Experimental Procedures), ranged from 5%
to 16%.
To analyze folate-mediated mitochondrial NAPDH produc-
tion, we employed proline as a reporter metabolite. The first
step in proline biosynthesis is catalyzed by the mitochondrial
enzyme P5CS which reduces gamma-glutamyl-phosphate to
pyrroline-5-carboxylate (P5C) using NADPH (Figure 3D). The
subsequent downstream steps in proline synthesis also involve
NAD(P)H-driven reduction, with compartmentalization de-
pending on the isozyme involved. In WT HEK293T cells fed
[2,3,3-2H]serine, after correction for the extent of serine label-
ing (but not the 2H-KIE, which has not been measured for the
ALDH1L2 reaction), we determined that 5% of proline contains
a hydrogen from serine. Deletion of either SHMT2 or MTHFD2
blocks this labeling, confirming that it occurs via mitochondrial
folate metabolism (Figure 3E). The labeling was decreased in
the ALDH1L2-deletion clone, indicating dedicated mitochon-
drial NADPH production by this enzyme (Figure 3E). To confirm
that the labeling does not involve conversion of NADH to
NADPH by nicotinamide nucleotide transhydrogenase (NNT)
(Leung et al., 2015), we knocked out NNT and observed
no impact on proline labeling (Figure 3F). The results with
endogenous fatty acid and proline reporters were confirmed
with engineered 2-hydroxygluturate reporters based on over-
expression of mutant IDH1 and IDH2 (Figure S3B) (Lewis
et al., 2014). Consistent with earlier results (Fan et al., 2014),
cell lines deficient in MTHFD2 or ALDH1L2 were sensitized
to oxidative stress in the form of hydrogen peroxide (Fig-
ure S3C). Thus, folate metabolism, substantially via ALDH1L2,
contributes to physiologically significant mitochondrial NADPH
production.
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(A) Fatty acid synthase combines malonyl-CoA and acetyl-CoA to synthesize saturated fatty acid chains. Deuterons from labeled NADPH will be incorporated
throughout the fatty acid chain in an amount depending on the extent of cytosolic NADPH labeling.
(B) Palmitate isotope labeling from [2,3,3-2H]serine. Data are corrected for natural isotope abundances. Inset shows calculated NADPH labeling fraction after
correction for the extent of serine labeling and the 2H-kinetic isotope effect.
(C) Palmitate labeling from [2,3,3-2H]serine in pancreatic cell line 8988T.
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Cell Metabolism 23, 1140–1153, June 14, 2016 1145
Folate Metabolism Produces Mitochondrial NADH and
Excess Formate
To measure the contribution of mitochondrial folate metabolism
to NADH production, we usedmalate as a reporter metabolite. In
the TCA cycle, malate dehydrogenase (MDH) catalyzes the
reversible conversion of NAD+ and malate into NADH and oxalo-
acetate (OAA) (Figure 4A). In HEK293T cells fed [2,3,3-2H]serine,
we observed substantial malate labeling. Quantitative analysis,
correcting for the extent of serine labeling and the 2H-KIE,
revealed that 7% of the NADH pool that reduces OAA to malate
incorporates a hydride from serine (Figure 4B). Labeling was
abolished in SHMT2 andMTHFD2-deletion cell lines, diminished
in the MTHFD1L-deletion cell, and only modestly affected in
the ALDH1L2 deletion. Thus, serine-driven mitochondrial flux
through MTHFD2 is a significant NADH source.
The magnitude of the 1C metabolism contribution to mito-
chondrial NADH was remarkable, given the high rate of NADH
production from the TCA cycle. Total mitochondrial NADH turn-
over can be estimated based on the cellular O2 uptake rate, with
80%of O2 uptake consumed by oxidative phosphorylation and
75% of oxidative phosphorylation driven by NADH (Fan et al.,
2013; Rolfe and Brown, 1997). Under these assumptions, a 7%
contribution of 1C metabolism to mitochondrial NADH requires
MTHFD2 flux of 3 mmol/L/s (liters of cell volume) (Figures
S4A and S4B; Experimental Procedures), which is roughly triple
the 1C unit flux required to support HEK293T cell biosynthetic re-
actions (0.8 mmol/L/s) (see Experimental Procedures). This raises
the possibility that 1C metabolism, under these nutrient-replete
conditions, runs in excess of 1C-unit demand.
To look directly for excess 1C units coming frommitochondrial
serine catabolism, we measured cellular excretion of serine-
derived CO2 and formate. Using [3-
14C]serine, we measured
flux of serine-derived carbon through the ALDH1L enzymes
into CO2, but the magnitude was small, consistent with the
extent of mitochondrial ALDH1L2-mediated NADPH production
(Figure S4B). In contrast, feeding cells [3-13C]serine and moni-
toring the production of [13C]formate by nuclear magnetic reso-
nance (NMR) revealed a large formate excretion flux. Serine-
derived [13C]formate was evident as a singlet NMR peak at
171.24 ppm, which was absent in MTHFD2-deletion cells,
against a background triplet peak resulting from [2H-13C]formate
internal standard (Figure 4C). Total formate excretion was equal
to nearly half of serine uptake in WT HEK293T cells, increased
yet more in the SHMT1-deletion cells, andwas absent in deletion
mutants for the core mitochondrial folate metabolism pathway
(Figure 4D). The total measured 1C unit production, combining
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(A) Malate dehydrogenase incorporates a hydride from NADH into malate.
(B) Calculated fraction ofmalate redox-active hydrogen derived from serine. 2H-labeling fraction ofmalate was corrected for the extent of [2,3,3-2H]serine labeling
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(F) Expression of 1C metabolism enzymes and excretion of formate for a set of proliferating human cell lines (mean ± SD, nR 3).
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biosynthetic demand, serine synthesis from glycine (Figures S4C
and S4D), CO2 release, and formate excretion, was 2.1 ±
0.2 mmol/L/s, in close agreement with the estimated MTHFD2
flux from NADH labeling (2.9 ± 0.3 mmol/L/s) (Figure 4E).
Changes to media serine concentration did not alter WT growth
rates but did reduce formate excretion (Figure S4E).
We then measured formate excretion across a set of prolifer-
ating human cell lines. Excretion rates varied considerably and
generally mirrored expression of the mitochondrial folate en-
zymes MTHFD2, SHMT2, and MTHFD1L (Figure 4F). Thus,
1C-unit production is not closely regulated to match biosyn-
thetic demand but instead depends on the expression level
of the mitochondrial pathway enzymes. The exception was
the pancreatic cell line 8988T, which despite expression of
SHMT2, MTHFD2, and the mitochondrial folate transporter
(Figure S4F) produced no measurable formate (low levels of
MTHFD1L expression were difficult to ascertain by our anti-
body). Consistent with the 2H-tracing data, this result
suggested that 8988T cells contain a mutation in a mitochon-
drial folate metabolism gene. We reverse transcribed and
sequenced the mRNAs of 1C metabolism genes from this cell
line and identified a 10-bp insertion between exons 8 and 9
of theMTHFD1L mRNA transcript (Figure S4G). This change re-
flects the introduction of an intronic de novo exon 9 splice
acceptor site at position 11 (NG_029185.1: g.57888A > G)
(Figure S4H). The variant was confirmed in 8988S, a sister
cell line to 8988T. We identified this MTHFD1L variant in the
ExAC database as a rare allele in the normal population, sug-
gesting that certain individuals harbor heterozygous mutations
in MTHFD1L, which may, due to loss of heterozygosity, result
in tumors defective in mitochondrial folate metabolism (Fig-
ure S4I) (Consortium et al., 2015).
Mitochondrial Folate Metabolism Mutants Require
Exogenous Serine and Glycine
WT HEK293T cells grow rapidly even in the absence of exog-
enous serine and glycine (Figure 5A). However, MTHFD2-dele-
tion cells are dependent upon both exogenous serine and
glycine for growth (Figure 5A), as were the 8988T cells natu-
rally defective in MTHFD1L (Figure S5A). When mitochondrial
folate metabolism mutant cells were starved for serine, growth
was restored by 1 mM formate (Figures 5B and S5B), indi-
cating that extracellular serine is required for the SHMT1 reac-
tion to meet 1C unit demand. Indeed, even though it did not
block growth, serine deprivation also led to 1C stress in WT
cells with the intact mitochondrial pathway, as indicated by
markedly enhanced intracellular AICAR (Figure 5C). This AI-
CAR increase, despite no change in the AMP/ATP ratio, was
sufficient to modestly activate AMP-activated protein kinase
(AMPK), as indicated by increased phosphorylation of both
AMPK itself and the classical AMPK substrate acetyl-CoA
carboxylase (ACC) (Figure 5D). Thus, 1C-unit sufficiency de-
pends on both extracellular serine and the mitochondrial 1C
pathway. Absence of both results in a severe enough 1C defi-
ciency to impair growth.
Similar to serine, and consistent with prior reports in mouse
embryonic fibroblasts and Chinese hamster ovary cells (Patel
et al., 2003; Stover et al., 1997), glycine was required to support
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Figure 5. Mitochondrial Folate Metabolism Mutants Are Dependent on Exogenous Serine and Glycine
(A) Growth of HEK293T and mthfd2D cell lines (plotted as log2[fold change in cell number]) in glycine- and serine-free media after 4 days.
(B) Growth of mthfd2D and shmt2D cells in serine-free media is rescued by 1 mM sodium formate.
(C) AICAR signal and AMP/ATP ratio after 1-hr serine withdrawal in WT HEK293T cells with and without formate (1 mM).
(D) Western blot of cells treated as in (C) shows phosphorylation of AMPK (T172) and ACC (S79) in response to serine withdrawal.
(E) Growth of mthfd2D and shmt2D cells requires glycine.
(F) Glutathione is depleted in mthfd2D and shmt2D cells grown without glycine.
(G) Growth ofmthfd2D cells in glycine-free media is restored by addition of reduced glutathione (GSH; 250 mM) or N-acetylcysteine (NAC; 250 mM) (mean ± SD,
nR 3).
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growth of MTHFD2 and SHMT2, but not SHMT1 knockout cells
(Figures 5E and S5C). Interestingly, formate did not rescue but
instead worsened growth (Figure S5D). Thus, glycine is not
needed to provide 1C units. To understand the metabolic con-
tribution of glycine, we performed metabolomic analysis on
glycine-deprived SHMT2 cells (Figure S5E). Among the stron-
gest metabolic changes was depletion of glutathione (g-glu-
tamyl-cysteinyl-glycine) (Figure 5F). This suggested that the
growth-impairment arose from antioxidant deficiency. Consis-
tent with this, either glutathione or N-acetylcysteine supplemen-
tation in the media rescued growth (Figure 5G). We conserva-
tively calculated cellular glycine demand (protein, purines, and
glutathione) and found it to be comparable to and likely in
excess of 1C demand (purines, dTTP). Thus, when it cannot
be imported, glycine is a critical product of folate metabolism
(Figure S5F), with folate-mediatedmitochondrial glycine produc-
tion supporting glutathione synthesis and associated redox
homeostasis.
MTHFD2 Knockout Impairs Colon Cancer Xenograft
Tumor Growth
Given the overexpression of mitochondrial folate metabolism
genes in cancer, we sought to test if cells lacking this pathway
could establish tumors in vivo. We generated MTHFD2-dele-
tion clones in the human colorectal cancer cell line HCT-116
(Figure 6A), which highly expresses mitochondrial folate meta-
bolism genes and rapidly excretes formate (Figure 4F). In stan-
dard DMEM, growth of the MTHFD2-deletion clones was
similar to the parental cell line (Figure 6B). As in the
HEK293T background, the HCT-116 MTHFD2-deletion cells
had massively elevated AICAR (Figure 6C), indicating 1C-unit
deficiency, and switched to cytosolic 1C-unit production as
indicated by M+2 labeling of dTTP and palmitate labeling
from [2,3,3-2H]serine (but not malate labeling) (Figures 6D–
6F). The HCT-116 MTHFD2-deletion cells also shared the de-
pendency of the HEK293T MTHFD2 knockout cells on exoge-
nous glycine and serine (Figures 6G–6I). Thus, in vitro, the
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Figure 6. Tumor Growth Is Attenuated in HCT-116 Cells Lacking MTHFD2
(A) Western blot of folate metabolism genes in HCT-116 cells and two MTHFD2-deletion clones.
(B) Cell growth in complete media.
(C) Steady-state AICAR levels.
(D) dTTP labeling from [2,3,3-2H]serine (48 hr).
(E) Fraction of malate redox-active hydrogen derived from serine as in Figure 4B.
(F) 2H-labeling into palmitate from [2,3,3-2H]serine. Inset shows associated NADPH-labeling fraction.
(G) Growth of HCT-116 cells in media without serine or glycine.
(H) Growth of HCT-116 mthfd2D_a cells requires either serine or formate (1 mM).
(I) Growth of HCT-116 mthfd2D_a cells requires either glycine of NAC (1 mM).
(J) Intratumor metabolite levels (AICAR and serine) from WT and deletion tumors implanted in CD-1 nude mice and measured by LC-MS (n = 8-10).
(K) Tumor growth (volume ± SEM as measured by calipers) in nude mice containing subcutaneous tumors from HCT-116 WT and mthfd2D cells (n = 10).
(L) Final tumor weights from tumor growth experiment in (K).
*p < 0.05, **p < 0.01, and ***p < 0.001 by unpaired t test.
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requirement for mitochondrial 1C metabolism depends on the
nutrient environment.
To evaluate growth in a tumor environment in vivo, we im-
planted WT and mutant cells onto the hind flanks of CD-1 nude
mice. Both WT and MTHFD2 mutant cells established tumors,
which we collected at small size (100 mg) to obtain samples
for metabolomics prior to substantial tumor necrosis. As in
cultured cells, AICAR levels were consistently high in the mutant
tumors (Figure 6J). Additionally, intratumor serine levels were
elevated, consistent with defective serine catabolism (Figure 6J).
The same changes in tumor metabolites were observed when
these cells were implanted in NOD severe combined immunode-
ficiency gamma (NSG) mice (Figure S6A). We next evaluated the
effect of this mutation on tumor growth. MTHFD2-deletion tu-
mors grew slower than WT controls and attained lower final tu-
mor weights in both nude and NSG mouse models (Figures 6K,
6L, S6B, and S6C); however, progressive tumor growth was
observed in all cases. Thus, mitochondrial 1C metabolism is
not required for either HCT-116 xenograft tumor initiation or
growth but does accelerate the tumor growth rate.
Reversal of SHMT1 Flux Enables Growth of
MTHFD2-Deletion Xenografts
The growth of MTHFD2 mutant tumors in vivo led us to ask
whether the mechanisms underlying this escape were the same
as we had observed in cell culture. Cells may overcome the 1C
deficit in vivo by reversing SHMT1 flux or by scavenging nutrients
such as purines, folates, and formate from the serum or surround-
ing tissues. To directly measure the source of 1C units in vivo, we
infused [2,3,3-2H]serine via jugular venouscatheter into nudemice
bearing bilateral HCT-116 xenografts, one WT and the other in
which MTHFD2 was deleted (Figure 7A). Steady-state circulating
serine labeling was achieved by 4 hr (Figure S7A), with substan-
tially greater cardiac than venous labeling indicating tissue uptake
of labeled serine and release of unlabeled serine (Figure 7A). The
serine infusion resulted in labeling of circulating formate, demon-
strating that circulating formate can originate from tissue serine
catabolism(asopposedtoexclusivelydietarysources) (Figure7B).
Total enriched serinewas nearly identical between themutant and
WT tumors (Figure7A).However,whenweanalyzeddTTP labeling
of tumors, large differenceswere apparent. Nearly 20%ofmutant
tumor dTTPwasM+2 labeled, indicating methylene-THF produc-
tion from serine via the cytosolic SHMT1 reaction (Figure 7B). In
contrast, only M+1 dTTP was observed in the WT tumors, indi-
cating mitochondrial generation of the 1C units from serine (Fig-
ure 7B). Thus, MTHFD2 mutant tumors in vivo acquire 1C units
via cytosolic serine catabolism.
We next tested whether SHMT1 flux was essential for tumor
growth in MTHFD2-deletion tumors. We generated a HCT-116
SHMT1-deletion cell line and a double-MTHFD2/SHMT1-dele-
tion cell line (Figures 7D and S7B–S7D). As expected, the double
mutant line was auxotrophic for formate (Figures 7E, S7E, and
S7F). In vivo, the SHMT1-deletion tumors engrafted and grew
comparably to the WT tumors (Figure 7F). In contrast, no tumors
formed from two separateMTHFD2/SHMT1 double-deletion cell
lines (Figures 7G, 7H, and S7G–S7I). While there is compart-
mental flexibility with respect to tumor 1C metabolism, intracel-
lular generation of 1C units from serine is essential for HCT-116
tumorigenesis.
DISCUSSION
Themammalian metabolic network is complex, with multiple po-
tential redundancies available to overcome nearly any single
disruption. Our work demonstrates the capability, using modern
genome-editing methods and isotope tracing, to comprehen-
sively dissect a complex multi-compartment pathway in
mammalian cells. The system we targeted, folate metabolism,
plays a central role in supporting cell growth in fetal develop-
ment, immune activation, and tumorigenesis. We quantitate
the mitochondrial folate metabolic fluxes that supply both 1C
units and glycine and determine the compensatory mechanisms
invoked when this metabolism is genetically ablated.
In addition, we re-examine the contribution of folate pathways
to redox metabolism. We previously established that deuterium
tracers could be used to probe both the sources and sinks of
NADPH (Fan et al., 2014). We showed that most cytosolic
NADPH is consumed by reductive biosynthesis. We further pro-
posed that NADPH could be produced from both cytosolic and
mitochondrial folate pathways and validated this in part using
small hairpin RNA (shRNA) against folate enzymes. Here, using
CRISPR knockout cell lines, we confirm the role of folate meta-
bolism in generating mitochondrial NADPH. These findings are
consistent with additional recent work demonstrating a role for
mitochondrial folate-mediated NADPH production in melanoma
metastasis (Piskounova et al., 2015). We find, however, that,
consistent with most prior literature on this topic, cytosolic 1C
pathway fluxes in most proliferating cells are typically running
in the direction from 10-formyl-THF to methylene-THF and
therefore are consuming, not producing, NADPH (Tibbetts and
Appling, 2010). Our prior assertion that most cells growing in
culture showed limited flux frommitochondrially derived formate
to purines, and accordingly generated formyl units in the cytosol
with concomitant NADPH production, was based on the obser-
vation that, even in transformed cells with active glycine cleav-
age, glycine does not contribute substantially to cytosolic 1C
units. However, in many of the cultured cell lines we have exam-
ined, absolute glycine cleavage flux is low relative to mitochon-
drial serine catabolism, diluting the glycine-derived signal in
isotope-labeling experiments and limiting the utility of this as a
compartmental tracer. While the metabolic role of glycine cleav-
age in cell culture remains unclear, the integrative genetic and
tracer analysis here, in support of the related prior literature,
effectively proves the predominance of mitochondrial 1C gener-
ation from serine in most cultured cells.
Importantly, while essentially all 1C units in many cell lines are
generated via mitochondrial serine catabolism, other cell lines
(the transformed renal epithelial cell line iBMK and the prostate
cancer cell line LNCaP) showed mixed cytosolic and mitochon-
drial 1C generation. The active utilization of the cytosolic 1C
pathway in these cells may relate to their tissue of origin; for
example, kidney expresses high levels of SHMT1. In yet other
cell lines, mitochondrial folate metabolism was overtly defective,
either due to endogenous mutations (8988T pancreatic cancer
cells) or engineered enzyme loss. In such cases, all 1C units
for nucleotide synthesis are derived in the cytosol and folate
metabolism becomes a substantial cytosolic NADPH source.
The relative ease of CRISPR-mediated gene knockout
enabled us to evaluate the impact of losing each of the core
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enzymes of the mitochondrial 1C pathway: SHMT2, MTHFD2,
and MTHFD1L. Common effects include high levels of AICAR,
glycine auxotrophy, and cytosolic 1C flux reversal. While the
MTHFD2 and MTHFD1L knockout cell lines grew normally,
loss of SHMT2 impaired cell growth in a manner that was
not rescued by formate. In addition, loss of SHMT2 was unique
in depleting mitochondrial metabolites. This suggests that
SHMT2 plays a role in mitochondrial health independent of 1C
cycling between the cytosol and mitochondria, likely related to
its ability to generate localized glycine and/or methylene-THF,
with the latter potentially needed to support mitochondrial thymi-
dine production (Anderson et al., 2011).
We find that, in HEK293T and HCT-116 cells, the cytosolic
enzyme SHMT1 runs in the direction of serine synthesis,
consuming glycine and 1C units. Indeed, one function of
SHMT1may be to avoid toxicity arising from inappropriate accu-
mulation of these species (Kim et al., 2015). Intriguingly, the rate
of formate elimination predicts resistance across species to the
dietary poison methanol (Sweeting et al., 2010), suggesting such
a detoxification role could be evolutionarily significant. Under
cytosolic 1C stress, however, SHMT1 can flip flux direction to
enable 1C-unit generation. This may be important in contexts
such as hypoxia or electron transport chain inhibition, where
an increased NADH/NAD+ ratio could impair mitochondrial 1C
flux. We find that, in the context of mitochondrial pathway dele-
tion, such serine catabolic flux by SHMT1 is the primary mode of
tumor 1C acquisition and essential for xenograft formation.
The absolute requirement for either SHMT1 or MTHFD2 activ-
ity in vivo, while a logical example of synthetic lethality, was
nevertheless somewhat surprising. The potential compensatory
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Figure 7. Growth of HCT-116 MTHFD2-Deletion Tumors Requires SHMT1
(A) Serine enrichment from steady-state infusion (130mg/kg/hr) of [2,3,3-2H]serine. Serum serine isotope labeling was obtained from cardiac puncture (top left) or
tail vein draw (bottom left) or from tumor metabolite extraction (bottom right) (n = 7).
(B) Serum formate concentration and labeling in mice that did or did not receive [2,3,3-2H]serine infusion (n = 4–8).
(C) dTTP 2H-labeling fraction from extracted tumors. M+2 dTTP is from cytosolic (SHMT1-mediated) serine-driven methylene-THF production; M+1 is from
mitochondrial serine catabolism.
(D) Schematic showing blocked reactions and potential for formate rescue (yellow highlighting) in SHMT1/MTHFD2 double-deletion cells.
(E) Growth of HCT-116 mthfd2D/shmt1D cells ± 1 mM formate.
(F) Growth of shmt1D xenografts (n = 10).
(G) Representative mice 8 weeks postinjection of mthfd2D (right) and mthfd2D/shmt1D (left) cells.
(H) Associated tumor growth curves (mean ± SEM, n = 12).
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mechanisms to circumvent MTHFD2 deletion in vivo are many
and involve both metabolic and genetic mechanisms. Metaboli-
cally, 1C-unit demand could have been met by circulating
formate, methyl-THF, purines, and pyrimidines. Genetically, an
isozyme of the MTHFD2 gene, MTHFD2L, encodes another
functional mitochondrial methylene-THF dehydrogenase, which
if expressed, would be expected to rescue mitochondrial 1C
metabolism. Finally, SHMT2 is constitutively found in not only
mitochondria but also the nucleus (Anderson and Stover,
2009). Given that the nucleus is thought to be in free metabolic
exchange with the cytosol, one would have anticipated that nu-
clear SHMT2 could substitute for SHMT1. The lack of rescue by
any of these mechanisms highlights the absolute dependence of
growing cells in vivo on intrinsic 1C metabolism and the poten-
tial, despite the pathway’s flexibility, for its rational therapeutic
targeting.
EXPERIMENTAL PROCEDURES
Generation of CRISPR Knockouts
Clonal CRISPR knockout cell lines were generated using the double nicking
variant of the published protocol of Ran and colleagues (Ran et al., 2013b).
Briefly, guide RNAs against exons of target genes (Table S1) were cloned
into a Cas9 nickase expression vector. Cells were transiently transfected using
Lipofectamine 2000 (Life Technologies) (HEK293T) or Fugene HD (Promega)
(HCT-116) and selected for 48 hr with 2 mg/mL puromycin. After selection, cells
were serially diluted in 96-well plates. SHMT1/MTHFD2 double-deletion cell
lines were selected for in media with 1 mM formate. Functional gene deletion
was confirmed by western blotting followed by targeted genomic sequencing.
Metabolite Profiling
Cells were grown in 6-cm tissue culture dishes for at least two doublings, dur-
ing which the medium was replaced every day (DMEM supplemented with
10% dialyzed fetal bovine serum; F0392, Sigma-Aldrich) and additionally
2 hr before extraction. Metabolism was quenched and metabolites were ex-
tracted by aspirating media and immediately adding 800 mL 80C 80:20
methanol:water extraction solution. For amino-acid-labeling experiments,
cells were washed three times with warm PBS before quenching with extrac-
tion solution. The resulting mixture was incubated on dry ice, scraped,
collected into a microfuge tube, and centrifuged at 5,000 3 g for 5 min. Insol-
uble pellets were re-extracted with 250 mL extraction solution. The superna-
tants were combined and dried under N2 and finally resuspended in water to
a dilution of 50 times the packed cell volume. Samples were analyzed by
reversed-phase ion-pairing chromatography coupled with negative-mode
electrospray-ionization high-resolutionMS on a stand-alone orbitrap (Thermo-
Fisher Exactive) (Lu et al., 2010).
Proliferation Assays
Standard proliferation assays were conducted in 24-well plates and relative
cell number measured using resazurin sodium salt. 2 3 104 cells were plated
in each well with 1 mL DMEM supplemented with 10% dialyzed fetal bovine
serum. For serine and glycine drop-out media, DMEM (4.5 g/L glucose and
4 mM glutamine) was formulated from scratch following standard procedures
(pH 7.4). Cell growth at each day was read as fluorescence intensity using a
Synergy HT plate reader (BioTek Instruments).
Mouse Xenografts
All animal studies were approved and conducted under the supervision of the
Princeton University Institutional Animal Care and Use Committee. For tumor-
growth studies, 6- to 7-week-old female CD1/nude mice were injected in the
rear flank with HCT-116 cells (13 106 cells in 100 mL). For the comparison be-
tween WT and MTHFD2 mutant growth, cells were implanted in individual an-
imals using Matrigel (50%), whereas for studies using SHMT1 deletions,
knockout and control cells were implanted bilaterally on the same animal in
growth media. Tumor growth measurements were taken biweekly using two
caliper measurements (volume = ½ [L 3 W2]). Animals were euthanized
when tumors reached 2,500 mm3 or if they displayed any signs of distress
or morbidity. For tumor metabolomic studies, 6- to 7-week-old female CD1/
nude or male NSG mice were bilaterally injected on the rear flank with HCT-
116 WT (right) and MTHFD2 mutant cells (left) (1 3 106 cells in 100 mL PBS).
Mice were sacrificed when control tumors had achieved an average size of
100 mg (5 mm) to avoid the development of tumor necrosis. Tumors
were removed and immediately frozen in liquid nitrogen for LC-MS analysis.
Isolated tumors were weighed, then 50 mg tissue was disrupted using a cryo-
mill and lysed in 1 mL ice cold 40:40:20 acetonitrile:methanol:water. Solids
were precipitated, spun down, and re-extracted with 1 mL lysis buffer. Com-
bined supernatants were dried down and resuspended in water to a concen-
tration of 50 mg/mL (original tumor mass) before analysis by LC-MS.
Mouse Infusion Studies
Six- to seven-week-old female CD1/nude mice (Charles River Laboratories)
were subcutaneously implanted with 1 3 106 HCT-116 cells (100 mL total vol-
ume) bilaterally on hind flanks. At an average tumor size of 50 mm3, jugular
venous catheters were placed following standard procedures (Kmiotek
et al., 2012). After surgery, mice were housed individually and allowed to
recover for a 1-week period before infusion of [2,3,3-2H]serine (400 mM in
PBS) at a rate of 130 mg/kg/hr over 4 hr. During the course of the experiment,
mice were allowed to move freely using a tethering apparatus (Instech Labo-
ratories) with no access to food. To assess venous tracer enrichment, blood
was sampled from tail vein 30 min before the end of the experiment. Tumors
were harvested under anesthesia, and a terminal cardiac draw was performed
to obtain serine enrichment in the cardiac serum.
Statistical Analysis
Samples sizes, error bars, and p values are defined in each figure legend. Re-
sults for technical replicates are presented as mean ± SD, for calculated
growth rates as mean ± 95% confidence interval and for tumor volumes
mean ± SEM. Growth rates were calculated by fitting to an exponential. Statis-
tical significance between conditions was calculated using an unpaired two-
tailed Student’s t test. All statistical calculations were performed using the
software package Prism 6.0g.
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